公开(公告)号：US20050065109A1

公开(公告)日：2005-03-24

申请号：US10659063

申请日：2003-09-10

申请人： Mitchell Fink ,  Russell Delude ,  Xianonan Han

发明人： Mitchell Fink ,  Russell Delude ,  Xianonan Han

IPC分类号： A61K31/7076

CPC分类号： A61K31/7076 ,  Y10S514/886 ,  Y10S514/921

摘要： A method of prophylaxis or treatment of inflammatory conditions, including, but not limited to, intestinal epithelial inflammation due to intestine-specific conditions (e.g., Crohn's disease or ulcerative colitis) or systemic causes of inflammation (e.g., endotoxemia, sepsis, hemorrhagic shock/resuscitation or pancreatitis) is disclosed. In the method of the invention, an affected patient is administered a therapeutically effective amount of a composition including an NAD-related compound, in a form that is accessible to a receptor molecule, conveyed in a pharmaceutically acceptable carrier vehicle. NAD-related compounds include nicotinamide adenine dinucleotide (NAD+), cyclic adenosine diphosphate ribose (cADPR), or functionally equivalent analogues, derivatives, metabolites or agonists thereof or prodrugs therefor. Also disclosed are ex vivo and in vivo assay methods to test candidate compounds for activity, kits for carrying out the therapeutic methods or the assay methods of the invention and articles of manufacture that include compositions for use in the methods of the invention and instructions for the use thereof.

摘要翻译： 包括但不限于由肠特异性病症引起的肠上皮炎症（例如克罗恩病或溃疡性结肠炎）或全身性炎症原因（例如，内毒素血症，败血症，出血性休克/ 复苏或胰腺炎）。 在本发明的方法中，给受影响的患者施用治疗有效量的包含NAD-相关化合物的组合物，其以在药学上可接受的载体载体中转运的受体分子可接近的形式。 NAD相关化合物包括烟酰胺腺嘌呤二核苷酸（NAD +），环状腺苷二磷酸核糖（cADPR）或功能等同的类似物，衍生物，代谢物或其激动剂或其前体药物。 还公开了用于测试候选化合物活性的离体和体内测定方法，用于实施本发明的治疗方法或测定方法的试剂盒和制品，其包括用于本发明方法的组合物和用于本发明方法的说明书 使用它。

公开(公告)号：US20060223887A1

公开(公告)日：2006-10-05

申请号：US11297114

申请日：2005-12-08

申请人： Mitchell Fink ,  Runkuan Yang ,  Russell Delude

发明人： Mitchell Fink ,  Runkuan Yang ,  Russell Delude

IPC分类号： A61K31/22 ,  A61K31/19 ,  A61K31/16

CPC分类号： A61K31/16 ,  A61K31/164 ,  A61K31/19 ,  A61K31/215 ,  A61K31/22 ,  A61K31/70

摘要： Disclosed is a method for treating acute pancreatitis in a subject. The method comprises the step of administering to the subject an effective amount of an ester of an alpha-ketoalkanoic acid or an amide of an alpha-ketoalkanoic acid.

摘要翻译： 公开了一种用于治疗受试者的急性胰腺炎的方法。 该方法包括向受试者施用有效量的α-酮链烷酸或α-酮链烷酸的酰胺的步骤。

公开(公告)号：US20050245609A1

公开(公告)日：2005-11-03

申请号：US11095031

申请日：2005-03-31

申请人： Mitchell Fink ,  Luis Ulloa ,  Kevin Tracey ,  Russell Delude

发明人： Mitchell Fink ,  Luis Ulloa ,  Kevin Tracey ,  Russell Delude

IPC分类号： A61K47/02 ,  A61K31/16 ,  A61K31/19 ,  A61K31/22 ,  A61P1/04 ,  A61P7/00 ,  A61P11/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P29/00

CPC分类号： A61K31/22 ,  Y02A50/411

摘要： This invention is directed to a method of using a therapeutic composition comprising an ester of an alpha-ketoalkanoic acid for the treatment of cytokine-mediated inflammatory conditions. The cytokine-mediated inflammatory conditions are mediated by, for example, Tumor Necrosis Factor (TNF), interleukin-1β (IL-1β)) or High Mobility Group B-1 (HMGB-1) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, rheumatoid spondylitis, osteoarthritis, gouty arthritis, endotoxic shock, cerebral malaria, silicosis, pulmonary sarcoidosis, bone resorption disease, graft versus host disease, allograft rejections, fever and myalgia due to infection, AIDS related complex (ARC), Crohn's disease, rheumatoid arthritis, cachexia and septic shock.

摘要翻译： 本发明涉及使用包含α-酮链烷酸酯的治疗组合物用于治疗细胞因子介导的炎性病症的方法。 细胞因子介导的炎性病症由例如肿瘤坏死因子（TNF），白细胞介素-1β（IL-1β））或高迁移率组B-1（HMGB-1）炎症介质介导。 示例性细胞因子介导的炎性病症包括但不限于类风湿性脊椎炎，骨关节炎，痛风性关节炎，内毒素性休克，脑疟疾，矽肺，肺结节病，骨吸收疾病，移植物抗宿主病，同种异体移植排斥，发热和肌肉酸痛 感染，AIDS相关复合物（ARC），克罗恩病，类风湿关节炎，恶病质和败血性休克。